Organon: A Surprising Deal
Organon shares have stabilized in recent times, with gradual debt reduction and structural growth allowing for a valuation re ...
Roivant Flips a Skin Drug to Organon
Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, ...
FiercePharma5d
Organon pays up to $1.2B to acquire Dermavant and its steroid-free skin cream Vtama
With its latest acquisition, women’s health outfit Organon is bringing its dermatology business to the U.S. with a ...
Court revives more than 500 lawsuits over Fosamax femur fracture risk
A U.S. appeals court on Friday revived more than 500 lawsuits alleging that Merck & Co failed to warn that its osteoporosis ...
pharmaphorum4d
Organon makes dermatology play with $1.2bn Dermavant buyout
Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, ...
Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B
Organon & Co (NYSE:OGN) has agreed to acquire Roivant Sciences Ltd’s (NASDAQ:ROIV) Dermavant Sciences Ltd, which is focused ...
CSR Wire6d
Organon Issues 2023 ESG Report, Highlighting Strides in Women’s Health Equity and Environmental Stewardship
Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, today released its 2023 Environmental, ...
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an ...
Barron's20h
Organon & Co.
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...